Lecanemab-ARIA: CD8+ T Cell Expansion & Brain Swelling

The cautious optimism surrounding lecanemab, the first FDA-approved disease-modifying therapy for early Alzheimer’s disease, is facing a growing wave of scrutiny. While initial trials showed modest cognitive benefits, a mounting body of evidence – detailed in recent publications (van Dyck et al., 2023; Honig et al., 2024; Shields et al., 2024) – reveals a complex safety profile and raises critical questions about the drug’s long-term impact on brain health. The emerging picture isn’t one of a simple cure, but a nuanced intervention that demands a far more precise understanding of patient selection and vigilant monitoring.

Lecanemab’s mechanism of action centers on clearing amyloid-beta plaques, a hallmark of Alzheimer’s disease. However, this clearance isn’t a passive process. It actively engages the immune system, specifically microglia and, crucially, adaptive immunity involving T cells (van Olst et al., 2025; Gate et al., 2020). The initial excitement focused on microglia-mediated clearance, but it’s becoming increasingly clear that CD8+ T cells play a far more significant – and potentially double-edged – role. These cells, normally responsible for eliminating infected or cancerous cells, are being recruited to the brain, where they contribute to both plaque removal and, alarmingly, vascular damage.

Recent studies (Jorfi et al., 2023; Chen et al., 2023) demonstrate that infiltrating CD8+ T cells can exacerbate neurodegeneration, particularly in the context of vascular inflammation. This is further complicated by the observation that these T cells can exhibit signs of exhaustion (Wherry & Kurachi, 2015; Akbar & Henson, 2011), potentially limiting their effectiveness and increasing the risk of off-target effects. The presence of clonally expanded CD8+ T cells in the cerebrospinal fluid of Alzheimer’s patients (Gate et al., 2020; van Olst et al., 2024) suggests a chronic, ongoing immune response, and raises questions about whether lecanemab is truly addressing the root cause of the disease or simply modulating an existing inflammatory process.

Furthermore, the metabolic state of these T cells appears critical. Research (Pearce, 2021; Pearce & Pearce, 2013; Chang et al., 2013; Cao et al., 2023) indicates that T cell function is heavily influenced by metabolic pathways, particularly glycolysis and hypoxia-inducible factors (HIFs). Dysregulation of these pathways can lead to T cell dysfunction and contribute to inflammation. The brain microenvironment, often characterized by hypoxia and metabolic stress, may exacerbate these vulnerabilities. Interestingly, senescent cells, which accumulate with age (Pereira et al., 2019), can also evade immune clearance via HLA-E, potentially contributing to chronic inflammation and hindering the effectiveness of lecanemab (Akbar & Henson, 2011; Pulko et al., 2016).

The Forward Look: The future of lecanemab, and amyloid-targeting therapies in general, hinges on a more sophisticated understanding of the immune response. We can anticipate several key developments:

• Biomarker-Driven Patient Selection: Expect a shift towards identifying patients most likely to benefit from lecanemab *and* least likely to experience severe adverse events. This will likely involve biomarkers beyond amyloid and tau, including measures of vascular health, immune cell function, and metabolic status.
• Immunomodulatory Strategies: Research will likely focus on combining lecanemab with immunomodulatory therapies to fine-tune the immune response, potentially mitigating inflammation and enhancing efficacy. Targeting T cell metabolism (O’Sullivan & Pearce, 2015; Scharping et al., 2016) and enhancing T cell mitochondrial function could be key strategies.
• Advanced Imaging Protocols: The need for more sensitive and precise imaging techniques to monitor ARIA and vascular changes will drive innovation in neuroimaging (Cogswell et al., 2025).
• Focus on Vascular Health: Given the link between amyloid immunotherapy and vascular damage (Taylor et al., 2024; Gross et al., 2019), interventions to improve cerebrovascular health may become integral to treatment protocols.

The initial promise of lecanemab remains, but it’s now clear that this is not a simple solution. The path forward requires a deeper dive into the complex interplay between amyloid pathology, the immune system, and the brain’s microenvironment. The next generation of Alzheimer’s therapies will likely be those that can harness the power of the immune system while minimizing its risks.